Dumping of Low Quality Drugs Affects Nepal Medicine Market
Posted on: Friday, 9 September 2005, 09:00 CDT
Dumping of low quality drugs affects Nepal medicine market
KATHMANDU, Sept. 8 (Xinhua) -- The growing trend of dumping low grade medicines in recent years has emerged as the most serious problem to the domestic medicine market of Nepal, a leading Nepali pharmaceutical entrepreneur said here Thursday.
"We have expressed serious concern over the Nepali government's negligence towards the problem," Hari Bhakta Sharma, executive director of Deurali-Janta Pharmaceutical, a private company that produces life-saving medicines, told reporters.
"In a small market like Nepal, more than 250 domestic and foreign companies are pumping their 12,000 products," Sharma said, adding, "How can we expect quality medicines in the market when overall quality checking capacity of the government's agency entrusted for the job is around 1,000 per year?"
Lack of brand awareness among the drugs users is also providing a favorable environment for the low quality medicines to penetrate into the domestic market, Sharma said.
The frequent obstruction in the distribution of essential medicines in the rural areas due to the conflict has also squeezed the access of quality medicines among the rural masses, Sharma noted.
"High priority given for imported medicines over crowded market, inadequate regulatory mechanism and technological gap are the major problems of the domestic pharmaceutical industries," he added.
Source: Xinhua News Agency - CEIS
Related Articles
- MDS Nordion Collaborates With Karpov Institute of Physical Chemistry to Develop Molybdenum-99 for Global Nuclear Medicine Market
- Market Potential for Hospital Services, Pharmaceuticals and Medical Devices in the US
- Latest Most Up-to-Date Cancer Personalized Medicine Market Report
- Learn About the World Regenerative Medicine Market
- TargetRx Releases 2007 Pharmaceutical Sales and Marketing Quality Analysis
- CombinatoRx to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
- SGX Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
- Up-to-Date Trends Are Available Today for the Complimentary and Alternative Medicine Market in the UK
- RGII Technologies and Bay Technologies Consulting Group Awarded Five-Year Contract to Maintain and Improve Navy Medicine Data Quality Program
 |
 |
User Comments (1)
| 1. |
Posted by Vivek Sharma on 06/25/2007, 05:30 In nepal, the pharmacueticals entreprenuars' saying and doing hardly match. The present market of Nepal is mostly corrupted by the Nepalese Pharmaceuticals companies. Even in DJPL, it goes for lots of free, and heavy promotions shemes to doctors. Most of the medicine related person know that Deurali Janta is known as the advocate for doing lots of lucrative promotion for drug promoters, not to drug users. For example, the amoxycilin of Deurali Janta costs NRs. 8, where as most of the international brands are selling below NRs. 5. The Nepalese manufacturing are hardly found of thinking of benefits of Nepali people, and Drug control authority is also coming under the illusion of nepali manufacturer. Nepali manufacturer only like to stop the foreign company so as to get the maximum benefit of monopoly, without caring about the poor people of Nepal. |
RSS Feeds